William Blair analyst Matt Larew has maintained their bullish stance on TMO stock, giving a Buy rating on April 17.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Larew has given his Buy rating due to a combination of factors, including Thermo Fisher’s ability to deliver results broadly in line with expectations while still generating upside at the earnings level. He highlights that core growth matched guidance and consensus, with particular strength in Lab Products and Pharma Services offsetting softer performance in other divisions.
Matt also points to management’s upcoming commentary on guidance, reshoring opportunities, and the company’s positioning in AI as important potential catalysts for future growth. In his view, clarity on segment trends, regional demand, and the pacing of growth into 2026 supports a constructive outlook, reinforcing the rationale for maintaining a positive stance on the shares.
According to TipRanks, Larew is an analyst with an average return of -1.6% and a 44.76% success rate. Larew covers the Healthcare sector, focusing on stocks such as Danaher, Thermo Fisher, and Twist Bioscience.
In another report released on April 17, Rothschild & Co Redburn also maintained a Buy rating on the stock with a $620.00 price target.